BANGKOK, Feb. 21, 2025 — NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”) clarified today that its February 20, 2025, press release, “NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director,” did not intend to suggest the Company had already met the Nasdaq Capital Market’s $2.5 million minimum stockholders’ equity requirement (the “Equity Rule”). The Company stated that during the first quarter to date, debt holders converted $2.3 million of debt to equity, and it drew down approximately $4.3 million from its Equity Line of Credit with White Lion Capital. As a result, NewGen believes its stockholders’ equity exceeds $2.5 million as of today. The Company is awaiting Nasdaq’s confirmation of compliance with the Equity Rule. However, there is no guarantee that Nasdaq will determine that the Company has regained compliance with the Nasdaq continued listing rules.

NewGen also confirmed that the Nasdaq Hearings Panel (the “Panel”) granted an extension for the Company to regain compliance with Nasdaq’s continued listing requirements, contingent upon meeting specific criteria within set timeframes. According to the Panel’s extension, the Company has progressed with its compliance plan (including the Equity Rule update mentioned above). This includes implementing a reverse split on February 11, 2025, to meet the $1.00 bid price requirement (NewGen’s closing bid price has been above $1.00 for six consecutive trading days as of February 19, 2025). The Company plans to apply for transition to the Nasdaq Capital Market on or before February 26, 2025.

About NewGen

NewGen offers comprehensive fertility services in Asia, assisting couples and individuals in accessing fertility treatments. Dedicated to helping individuals and couples build families, NewGen focuses on expanding access to infertility treatment and providing comprehensive fertility services. NewGen’s management team has over a decade of collective experience in the fertility industry. NewGen operates clinics in Thailand, Cambodia, and Kyrgyzstan, providing a full range of services, including infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, where permitted. For more information, visit . Information on NewGen’s website is not incorporated into this press release and should not be considered part of it.

Forward-Looking Statements

This press release includes forward-looking statements made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are generally identified by terms like “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These statements include descriptions of the Company’s future commercial operations, business strategy, and financial condition. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from these statements. Readers should carefully consider these factors and the risks and uncertainties described in the Company’s annual report on Form 20-F and other filings with the SEC, which could cause actual results to differ materially from those in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information is current as of this press release date, and the Company does not undertake to update any forward-looking statement, except as required by law.

Investor Relations Contact

ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: